Baseline characteristics of patients treated with lenalidomide
| Characteristic . | Lenalidomide (n = 32) . |
|---|---|
| Age (y) | |
| Median (range) | 64 (25-83) |
| Gender | |
| Male | 15 |
| Female | 17 |
| Race | |
| White | 24 |
| Black | 7 |
| Hispanic | 1 |
| TNMB stage | |
| IB | 7 |
| IIA | 2 |
| IIB | 6 |
| III | 7 |
| IVA | 8 |
| IVB | 2 |
| Erythrodermic MF | 3 |
| Sézary syndrome | 11 |
| Prior treatments | |
| Median (range) | 6 (1-14) |
| Systemic | 4 (0-12) |
| Skin directed | 2 (0-6) |
| Characteristic . | Lenalidomide (n = 32) . |
|---|---|
| Age (y) | |
| Median (range) | 64 (25-83) |
| Gender | |
| Male | 15 |
| Female | 17 |
| Race | |
| White | 24 |
| Black | 7 |
| Hispanic | 1 |
| TNMB stage | |
| IB | 7 |
| IIA | 2 |
| IIB | 6 |
| III | 7 |
| IVA | 8 |
| IVB | 2 |
| Erythrodermic MF | 3 |
| Sézary syndrome | 11 |
| Prior treatments | |
| Median (range) | 6 (1-14) |
| Systemic | 4 (0-12) |
| Skin directed | 2 (0-6) |
TNMB, tumor, node, metastasis, blood.